Novo Nordisk

News

Novo’s $16.5bn Catalent deal cleared by EU Commission

EU says Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation Catalent does not pose antitrust issues.

News

Zepbound tops Wegovy in first head-to-head weight-loss trial

Eli Lilly is playing catch-up to Novo Nordisk in the fast-growing obesity therapy sector but has new data that could tip the balance in its favour.

News

Novo sheds kidney drug licensed for $1.3bn a year ago

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.

News

Wegovy romps ahead after key rival sees slowdown

Novo Nordisk's sales of blockbuster obesity drug Wegovy grew by a massive 79% in the third quarter, in a relief to investors after disappointing results three months ago.

News

Representation of Ascendis Pharma technology

Novo puts $285m into monthly GLP-1 based on Ascendis tech

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.

News

Slide showing non-alcoholic fatty liver disease (NAFLD)

Novo Nordisk will file semaglutide for MASH next year

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US

Novo’s $16.5bn Catalent deal cleared by EU Commission

Zepbound tops Wegovy in first head-to-head weight-loss trial

Novo sheds kidney drug licensed for $1.3bn a year ago

Wegovy romps ahead after key rival sees slowdown

Novo puts $285m into monthly GLP-1 based on Ascendis tech

Novo Nordisk will file semaglutide for MASH next year

Consolidating data strategy for global success: Insights fro...

How to meet your physicians where they are online

Novo Nordisk

Editor's Picks